The case for a Klebsiella pneumoniae vaccine: A public health priority

The review covers several key areas of vaccine development, including conjugate vaccines, nanovaccines, and bioconjugate approaches, which have shown potential in eliciting immune responses. Conjugate vaccines, which couple polysaccharides with carrier proteins, have been explored to target capsular polysaccharides and lipopolysaccharides, two critical components of K. pneumoniae's virulence mechanisms. Nanotechnology-based vaccines offer innovative solutions by enhancing antigen stability and immune response. Additionally, reverse vaccinology and immunoinformatics have been used to design multiepitope vaccines targeting conserved antigens. The review underscores the challenges in advancing these vaccines through clinical trials and emphasizes the need for ongoing research to develop effective, broad-spectrum vaccines to combat K. pneumoniae infections.